Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANCICLOVIR vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including AIDS patients.,Prevention of CMV disease in transplant recipients at risk.,Treatment of CMV pneumonitis, colitis, esophagitis, and other CMV infections in immunocompromised patients (off-label).,Treatment of herpes simplex virus (HSV) infections resistant to acyclovir (off-label).
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for Cr Cl <70 m L/min
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Ganciclovir is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. Less than 1% is metabolized to 9-[(1,3-dihydroxy-2-propoxymethyl)guanine].
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
1-2% bound; primarily to albumin (low binding)
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.47-0.74 L/kg; indicates extensive distribution into tissues including brain, eye, and lungs
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 6-9% (fasting); increased to 30% with food due to enhanced absorption
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl ≥70 m L/min: 5 mg/kg q12h (induction), 5 mg/kg q24h (maintenance); Cr Cl 50-69: 2.5 mg/kg q12h, then 2.5 mg/kg q24h; Cr Cl 25-49: 2.5 mg/kg q24h, then 1.25 mg/kg q24h; Cr Cl 10-24: 1.25 mg/kg q24h, then 0.625 mg/kg q24h; Cr Cl <10: 1.25 mg/kg 3 times/week after hemodialysis. Oral: Cr Cl ≥70: 1000 mg tid; 50-69: 1500 mg qd or 500 mg tid; 25-49: 1000 mg qd or 500 mg bid; 10-24: 500 mg qd; <10: 500 mg 3 times/week after dialysis.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for hepatic impairment. Use with caution in severe hepatic dysfunction due to limited data.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral dosing in children ≥9 years: 1000 mg three times daily with food; for children <9 years, use weight-based: 30 mg/kg per dose (max 1000 mg) three times daily.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustments beyond renal function. Closely monitor renal function and adjust dose based on Cr Cl.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Ganciclovir is associated with granulocytopenia, anemia, and thrombocytopenia. Animal studies have shown that ganciclovir is carcinogenic, mutagenic, and causes impairment of fertility and teratogenicity. It is indicated only for the treatment of CMV retinitis and prevention of CMV disease in transplant recipients. Not approved for congenital or neonatal CMV disease.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow suppression, especially in patients with pre-existing cytopenias or on concomitant myelosuppressive drugs.,Renal impairment: Dose adjustment required; increased risk of toxicity in renal dysfunction.,Carcinogenicity and mutagenicity: Anticipated in humans based on animal data.,Teratogenicity: Embryotoxic and teratogenic in animals; use only if benefit outweighs risk.,Interaction with mycophenolate mofetil: May increase risk of hematologic toxicity.,Electrolyte disturbances: May cause hypocalcemia, hypokalemia, hyponatremia.,Ocular effects: Retinal detachment in patients with CMV retinitis (not directly drug-related).,Seizures and neurotoxicity: Rare, especially in patients with CNS conditions or renal impairment.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to ganciclovir, valganciclovir, or any component of the formulation.,Absolute neutrophil count < 500 cells/μL, platelet count < 25,000/μL, or hemoglobin < 8 g/d L (relative contraindication due to risk of worsening cytopenias).,Pregnancy (avoid unless potential benefit outweighs risk; embryotoxic in animals).
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Take ganciclovir with food to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase drug levels (weak interaction). No specific food restrictions otherwise.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benefit outweighs risk. Second/third trimester: potential for bone marrow suppression and nephrotoxicity in fetus; use only if clearly needed.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Not recommended. M/P ratio unknown; ganciclovir is excreted into breast milk in rats. Potential for severe adverse effects in nursing infant (e.g., bone marrow suppression, carcinogenesis).
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific pregnancy dosing adjustments established. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; monitor drug levels if available. Standard dosing: 5 mg/kg IV q12h x 14-21 days (induction), then 5 mg/kg/day (maintenance). Adjust for renal function (Cr Cl). Use lowest effective dose.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Monitor renal function closely; dose adjustment required in renal impairment. Ganciclovir is myelosuppressive; check CBC frequently, especially in patients with neutropenia. Use with caution in patients with pre-existing cytopenias. Administer IV infusion over at least 1 hour to reduce renal toxicity. Valganciclovir, the prodrug, is only for CMV retinitis in immunocompromised patients. Always maintain adequate hydration to prevent crystalluria.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Ganciclovir may lower your blood cell counts, increasing risk of infection, bleeding, or anemia. Report any signs of infection (fever, chills), unusual bruising/bleeding, or fatigue immediately.,Keep all appointments for blood tests and kidney function monitoring.,Drink plenty of fluids to prevent kidney problems.,Use effective contraception during treatment and for at least 30 days after stopping for females, and for 90 days for males; ganciclovir can harm an unborn baby.,Do not breastfeed during treatment due to potential harm to the infant.,Avoid driving or operating machinery if you experience dizziness, confusion, or seizures.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Probenecid inhibits renal tubular secretion of ganciclovir, reducing its clearance and increasing its plasma concentration. This can potentiate the antiviral effect but also elevates the risk of dose-dependent adverse effects such as myelosuppression and nephrotoxicity. Concurrent use may require dose adjustment of ganciclovir and monitoring for toxicity."
"Combined use of ganciclovir and zidovudine results in additive myelosuppression, particularly neutropenia and anemia, due to overlapping bone marrow toxicity. This interaction increases the risk of severe hematologic adverse effects, including life-threatening infections and transfusion-dependent anemia. Patients with pre-existing cytopenias or those receiving other myelotoxic agents are at heightened risk."
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANCICLOVIR vs ACTIQ, answered by our medical review team.
GANCICLOVIR is a Antiviral that works by Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANCICLOVIR and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANCICLOVIR is: Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANCICLOVIR and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANCICLOVIR is classified as Category D/X. FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benef. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.